Federal Supply Schedule 36F79726D0181
Award Date 8/15/26
Last Date to Order 8/14/31
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed Similar IDVs
- GSA issued a Federal Supply Schedule contract to Takeda Pharmaceuticals America, Inc. under FSS Schedule 65 IB (Drugs, Pharmaceuticals, & Hematology Related Products) on February 15, 2026, with an ultimate completion date of August 14, 2026 and a contract ceiling of $25,000. This is a multiple-award schedule vehicle administered by Veterans Integrated Service Network 12 on behalf of the Department of Veterans Affairs. Takeda is approved to supply drugs, pharmaceuticals, and...
- Takeda Pharmaceuticals America Inc., a subsidiary of Japan-based Takeda Pharmaceutical Company Limited, holds a multiple-award General Services Administration (GSA) Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs, awarded February 15, 2016, with an ultimate completion date of February 14, 2026, and a ceiling value of $719,535,960.00. The contract operates without set-aside designation due to the specialized and often single-source nature of the biopharmaceutical...
- GSA issued a Federal Supply Schedule contract to Takeda Pharmaceuticals America, Inc. under the Pharmaceuticals and Drugs (FSS-61-IB) schedule on March 1, 2011, with a ceiling value of $54.5 million and an ultimate completion date of September 30, 2018; this contract was canceled effective July 9, 2026 and replaced by a new contract. The contract covered FSC Group 65, Part I, Section B — drugs, pharmaceuticals, and hematology-related products — as a multiple-award vehicle. Performance occurred...
- Takeda Pharmaceuticals America, Inc., a foreign-owned subsidiary based in Cambridge, Massachusetts, was awarded a multiple-award Federal Supply Schedule contract (FSS-61-IB) for Drugs, Pharmaceuticals, and Hematology-Related Products by Veterans Integrated Service Network 12, effective September 15, 2025, through September 28, 2030. The contract carries a ceiling value of approximately $2.89 billion with no small business set-aside designation. This indefinite delivery vehicle serves as a...
- The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...
- Takeda Pharmaceuticals America Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs National Acquisition Center for specialized pharmaceutical products valued at $131.0 million, effective July 15, 2025, through March 12, 2026. This child contract operates under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and covers nine therapeutic agents: CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE, VPRIV, FIRAZYR,...
- GSA issued a Federal Supply Schedule contract to Daiichi Sankyo, Inc. under the Pharmaceuticals and Drugs Schedule (FSS-61-IB) on April 15, 2018, with a ceiling value of $411.9 million. This is a multi-agency, catalog-based vehicle through which federal agencies place delivery orders against Daiichi Sankyo's price list without running new competitions. Daiichi Sankyo specializes exclusively in supplying TURALIO (pexidartinib), a specialized pharmaceutical indicated for treating tenosynovial...
- GSA issued a Federal Supply Schedule contract to Sanofi-Aventis U.S. LLC under the Pharmaceuticals and Drugs (FSS-61-IB) schedule on June 1, 2023, with a ceiling value of $4.96 billion and performance through May 31, 2028. The contract covers drugs, pharmaceuticals, and hematology-related products under Schedule 65 I B. Performance occurs nationwide; the funding federal agency is Veterans Integrated Service Network 12. The schedule is a multiple-award vehicle, meaning agencies may issue orders...
- GSA issued a Federal Supply Schedule contract to Sumitomo Pharma America, Inc. on the Pharmaceuticals and Drugs schedule (FSS-61-IB) effective July 1, 2019, with a ceiling value of $2.532 billion and completion date of January 31, 2027. The contract covers Special Item Number 65 I B (drugs, pharmaceuticals, and hematology-related products) and operates as a multiple-award schedule vehicle through which federal agencies order directly from the contractor's price list. Performance is nationwide....
- GSA issued a Federal Supply Schedule contract to Eisai Inc. under the Pharmaceuticals and Drugs (FSS-61-IB) schedule on June 1, 2024, for drugs, pharmaceuticals, and hematology-related products, with a contract ceiling of $361.7 million and performance extending through May 31, 2029. The contract operates as a multiple-award schedule vehicle, allowing federal agencies and authorized users to place orders directly against Eisai's price list without conducting new competitions. Eisai holds no...